AI Article Synopsis
Article Abstract
Objectives: In this case series, we present 5 cases of autoimmune rheumatic disease onset shortly after receiving mRNA vaccination against coronavirus disease 2019 (COVID-19).
Methods: We identified 5 patients from Brooke Army Medical Center who developed new manifestations of rheumatic disease following the second dose of the Pfizer-BioNTech or Moderna COVID-19 vaccinations. All patients were initially seen in primary care and then referred to rheumatology for further evaluation and management. Clinical data were obtained through review of the electronic medical record.
Results: Three cases involve elderly women with insidious onset of symmetric wrist and hand polyarthritis with seropositivity for rheumatoid factor. One case involves an elderly woman with a subacute onset of lower extremity-predominant, symmetric polyarthritis. One case involves an elderly man with insidious onset of bilateral shoulder and hip stiffness and arthralgias in the setting of elevated erythrocyte sedimentation rate and a rapid response to glucocorticoid therapy.
Conclusion: Whether there exists a causal or contributory relationship between COVID-19 mRNA vaccination and the development of autoimmune rheumatic disease remains to be determined. Ultimately, further research is needed to establish if there is a true connection between the two.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940785 | PMC |
| http://dx.doi.org/10.1097/RHU.0000000000001906 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study.
Rheumatology (Oxford)
December 2024
Centre for Rheumatic Diseases, Department of Inflammation Biology, King's College London, London, UK.
Objectives: To update the first-line conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) prescribing pattern, describe change and variation across demographical and geographical factors in the Rheumatoid arthritis (RA) population, and identify individual and hospital factors associated with it.
Methods: This retrospective cohort study included newly diagnosed RA adult patients from 1 May 2018-1 April 2023 in the UK. We used adjusted multinomial logistic regression with random effect to explore associations with different first-line csDMRAD prescription and to account for hospital-level clustering.
The impact of an online, lifestyle intervention program on the lives of patients with a rheumatic and musculoskeletal disease: a pilot study.
Rheumatology (Oxford)
December 2024
Department of Rheumatology, Erasmus MC, Rotterdam, The Netherlands.
Objectives: To evaluate the short and long term effects of an online, interactive, multifactorial lifestyle intervention program (Leef! Met Reuma) on health risk and all ICHOM-recommended patient reported outcome measures(PROMs) in patients with an Inflammatory Arthritis(IA), OsteoArthritis(OA) or FibroMyalgia(FM).
Methods: Patients with an IA, OA or FM, could register for the lifestyle intervention program. The program consists of a 3-month intensive part followed by a 21-month aftercare period and focuses on 4 pillars, namely nutrition, exercise, relaxation and sleep.
Spondyloarthritis and Risk of Malignancy: A Narrative Review on a Still Controversial Issue.
Rheumatol Ther
December 2024
University of Milan, Fondazione IRCCS Istituto Nazionale del Tumori, Milan, Italy.
Current literature regarding cancer risk in rheumatic and musculoskeletal diseases (RMDs) is particularly poor and controversial, even though the incidence of malignancy in some patients with RMDs is considered to be increased compared with the general population. Malignancy may be a major comorbidity in subjects with spondyloarthritis (SpA) as the result of multifactorial mechanisms, from disease pathogenesis to the iatrogenic effect of immunomodulating drugs. Several recommendations for screening and management of cancer risk have been developed in recent years with the aim of improving the different outcomes in these patients.
View Article and Find Full Text PDFFrequency of severe infections in rheumatic disease patients receiving bDMARDs post-kidney transplantation: a multicenter study.
Clin Rheumatol
December 2024
Department of Rheumatology, Faculty of Medicine, Dokuz Eylul University, İnciraltı Mahallesi Mithatpaşa Cad. no:1606, Balçova, İzmir, Türkiye.
Objectives: To evaluate the incidence and characteristics of severe infections in rheumatic patients receiving biologic disease-modifying anti-rheumatic drugs (bDMARDs) after kidney transplantation.
Methods: This multicenter, retrospective study included 38 patients who had undergone kidney transplantation and received bDMARDs for rheumatic diseases. Demographic, clinical, and treatment data were collected.
Sliding Hydrogels Reveal the Modulation of Mechanosensing Attenuates the Inflammatory Phenotype of Osteoarthritic Chondrocytes in 3D.
J Biomed Mater Res A
January 2025
Department of Bioengineering, Stanford University, Stanford, California, USA.
Osteoarthritis (OA) is a prevalen degenerative joint disease with no FDA-approved therapies that can halt or reverse its progression. Current treatments address symptoms like pain and inflammation, but not underlying disease mechanisms. OA progression is marked by increased inflammation and extracellular matrix (ECM) degradation of the joint cartilage.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!